Enlivex Therapeutics Ltd
(XTAE:ENLV)
₪
4.71
-0.05 (-1.05%)
Market Cap: 95.93 Mil
Enterprise Value: 1.38 Mil
PE Ratio: 0
PB Ratio: 0.89
GF Score: 22/100 Enlivex Therapeutics Ltd at Jefferies Healthcare Conference Transcript
Jun 09, 2023 / 03:30PM GMT
Claire Duffy
(Trades, Portfolio) LLC - Analyst
Welcome to the Jefferies Global Healthcare Conference. My name is Claire. And I'm with the banking team. And it's my pleasure to introduce Oren Hershkovitz, CEO of Enlivex Therapeutics.
And with that, I will hand it off to him.
Oren Hershkovitz
Enliven Therapeutics, Inc. - CEO
Thank you very much. Hello, everyone, pleasure to be here and present Enlivex. As mentioned, my name is Oren Hershkovitz, I'm the CEO of Enlivex Therapeutics, which is an off-the-shelf, universal, macrophage reprogramming cell therapy that's focused on developing therapies for life-threatening unmet medical conditions.
So I'll start with explaining what we do in general and where we are positioned. So Enlivex is a next
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot